Carvykti Injection, Suspension
NDC 57894-111
View dosage, usage, ingredients, routes, and UNII mappings.
Product Information
Carvykti (ciltacabtagene autoleucel) is a BLA-approved product labeled by Janssen Biotech, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection, suspension for intravenous administration. This product entry covers the primary NDC 57894-111 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
NDC Product Code:
57894-111
Proprietary Name:
Carvykti
Non-Proprietary Name: [1]
Ciltacabtagene Autoleucel
Substance Name: [2]
Ciltacabtagene Autoleucel
NDC Directory Status:
Cellular Therapy
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Code Navigator:
Clinical Specifications
Dosage Form:
Injection, Suspension
- A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route(s): [4]
Intravenous - Administration within or into a vein or veins.
Labeler & Regulatory Data
Labeler Name: [5]
Labeler Code:
57894
Product Label ID:
HCPCS Code:
Q2056
- Ciltacabtagene car-pos t
FDA Application Number: [6]
BLA125746
Marketing Category: [8]
BLA - A product marketed under an approved Biologic License Application.
Marketing Timeline
Start Marketing Date: [9]
02-28-2022
Listing Expiration Date: [11]
12-31-2027
Exclude Flag: [12]
N
Code Structure Chart
Product Details
What is NDC 57894-111?
The NDC code 57894-111 is assigned by the FDA to the product Carvykti. It is commonly known by its generic name, ciltacabtagene autoleucel. This pharmaceutical product is labeled by Janssen Biotech, Inc. and is currently categorized as listed product. The medication is a injection, suspension administered via intravenous route. In terms of distribution, this product is available in 2 different package configurations. The associated package NDC(s) include: 57894-111-01, 57894-111-02. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.
What are the uses of this product?
CARVYKTI is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
What are Active Ingredients of this product?
An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CILTACABTAGENE AUTOLEUCEL (UNII: 0L1F17908Q)
- CILTACABTAGENE AUTOLEUCEL (UNII: 0L1F17908Q) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- DIMETHYL SULFOXIDE (UNII: YOW8V9698H)
What is the NDC to RxNorm Crosswalk for this product?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 2594780 - ciltacabtagene autoleucel 100,000,000 CELLS in 70 ML Injection
- RxCUI: 2594780 - 70 ML ciltacabtagene autoleucel 1430000 CELLS/ML Injection
- RxCUI: 2594780 - ciltacabtagene autoleucel 100,000,000 CELLS per 70 ML Injection
- RxCUI: 2594786 - CARVYKTI 100,000,000 CELLS in 70 ML Injection
- RxCUI: 2594786 - 70 ML ciltacabtagene autoleucel 1430000 CELLS/ML Injection [Carvykti]
* Please review the full disclaimer at the bottom of this page.
Patient Education
Ciltacabtagene Autoleucel Injection
Ciltacabtagene autoleucel is used to treat multiple myeloma (a type of cancer of the bone marrow) in adults that has returned or that did not respond to at least 4 other treatments. Ciltacabtagene autoleucel is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. It works by causing the body's immune system (a group of cells, tissues, and organs that protects the body from attack by bacteria, viruses, cancer cells, and other substances that cause disease) to fight the cancer cells.
[Learn More]
* Please review the full disclaimer at the bottom of this page.
Product & Regulatory Definitions
What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
What is the Substance Name? An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
What are the Administration Routes? The translation of the route code submitted by the firm, indicating route of administration.
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".
